2012
A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer.
Gettinger S, Rizvi N, Shepherd F, Chow L, Laurie S, Spigel D, Sbar E, Shen Y, Brahmer J. A phase I study of BMS-936558 in combination with gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel in patients with treatment-naive, stage IIIB/IV non-small-cell lung cancer. Journal Of Clinical Oncology 2012, 30: tps2615-tps2615. DOI: 10.1200/jco.2012.30.15_suppl.tps2615.Peer-Reviewed Original ResearchBMS-936558Cell lung cancerAdverse eventsTreatment armsLung cancerDisease progressionAnti-PD-1 monoclonal antibodyStage IIIB/IV NSCLCPlatinum-based doublet chemotherapyStage IIIB/IVImpressive tumor responsesCarboplatin/paclitaxelDisease control rateIIIB/IVFirst-line standardPD-1 expressionSerious adverse eventsDose-limiting toxicityGemcitabine/cisplatinPhase 1 studyPlatinum-based chemotherapyPhase 1 trialCancer-related mortalityOverall response rateWithdrawal of consent
2011
Lung Cancer in Older Patients
Gettinger S, Tanoue L. Lung Cancer in Older Patients. Respiratory Medicine 2011, 89-109. DOI: 10.1007/978-1-60761-727-3_5.Peer-Reviewed Original ResearchYears of ageLung cancerOlder patientsBest supportive careMajority of patientsCancer-related mortalityStandard of careNovel therapeutic approachesLung cancer diagnosisAdvanced diseaseElderly patientsSupportive careMedian ageClinical trialsClinical studiesAggressive approachTherapeutic approachesPatientsCancerOlder populationYounger counterpartsCancer diagnosisAgeMortalityDisease